Pia Angeli T.

Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

Source: JCM | Free Full-Text | Therapeutic Options for the Treatment of Interstitial Lung Disease Related
to Connective Tissue Diseases. A Narrative Review | HTML (mdpi.com)

1
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

2
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

3
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

4
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

5
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

6
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

7
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

8
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

9
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

10
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

P I C O
Population Patient Intervention Comparison Outcome
Problem or E x p o s u r e
 Treatment is often  few adverse events were  ILD represents one of
 patients with based on steroids found among the treated the most severe
ILD and conventional patients, without any clinical manifestation
 Due to the immunosuppressive statistical difference of CTDs with a deep
poor drugs, but the compared to the placebo impact on the
knowledge of recent publication group, suggesting an prognosis in terms of
CTD-ILD’s of the encouraging improved safety profile of morbidity and
natural history results of the intravenous CYC compared mortality.
and due to INBUILD trial has with oral CYC  there is still lack of
the difficulties highlighted a
 authors compared the prospective data
related to possible effective
efficacy and safety of two- about prevalence,
design of and safe use of
year MMF treatment vs. follow-up, and
randomized antifibrotic drugs as
one-year oral CYC followed therapeutic approach
control trials, a new therapeutic
by placebo for an additional  therapeutic approach
there is a lack option for these
year>>> MMF treatment led in clinical practice is
of prospective subjects. 
to a significant improvement usually based on the
data about in FVC and dyspnea in the
the use of steroids and
course of 24 months of immunosuppressive
prevalence, follow-up, without a
follow-up, and drugs, mainly CYC,
difference between the two MMF, and AZA, both
therapeutic treatment groups
efficacy.  for steroid-sparing
 The ASTIS trial compared purposes and for
HSCT with CYC pulse unresponsive patients
therapy in 156 patients with  a possible effective
early diffuse SSc. HSCT and safe use of
was associated with Nintedanib in patients
increased treatment-related presenting with
mortality in the first year, but progressive fibrosing
significantly improved long- ILDs other than IPF,
term event-free survival and including subjects
overall survival with CTD
 adjusted survival was not
significantly different among
subgroups of IIM-ILD
patients compared with IPF
patients after lung
transplantation

Source: 40674_2016_38_Article 69..84 (springer.com)

11
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

P I C O
Population Patient Intervention Comparison Outcome
Problem or E x p o s u r e

 Scleroderma is a rare  subacute onset of tender,  A full-thickness skin  Promising results

autoimmune disorder, painful symmetric induration of biopsy reveals fibrosis of have been
with a national annual the subcutaneous tissues, the dermis with extension demonstrated with
incidence of 20 cases skin is initially edematous to the subcutaneous fat imatinib mesylate,
per million in the USA bearing a peau d’orange^ septae. An inflammatory
a tyrosine kinase
and an estimated appearance, woody induration infiltrate is notably absent
prevalence of 150– of the subcutaneous tissues  a list of scleroderma
inhibitor but short-
300 cases per million with evidence of puckering of mimics, categorized as lived
 Type 1 (Scleredema the skin and the characteristic immune-mediated,  knowledge of their
adultorum of venous groove sign evident on metabolic, hereditary, key distinguishing
Buschke) is the elevation of the affected limb deposition, and toxin- features will prove
most prevalent type  hallmark histopathologic induced disorder helpful in
and primarily feature of eosinophilic fasciitis  A broad differential determining the
affects individuals is the presence of dermal- diagnosis is required etiology of a
less than 20 years, hypodermal sclerosis when evaluating a patient patient’s
associated with fibrotic with increased thickness
occasionally cutaneous fibrosis
thickening of the of the skin
occurring in and ultimately
subcutaneous adipose lobular  Particular attention
children facilitate the
septae, superficial fascia, and should be paid to the
 Type 3 scleredema, perimysium implementation of
quality and distribution of
(scleredema  Corticosteroids are considered appropriate
cutaneous involvement,
diabeticorum) is to be the first-line therapeutic the presence or absence therapy where
more commonly agent, with demonstrated of Raynaud’s indicated
observed in patients efficacy in more than 70 % of phenomenon, findings on
with long-standing patients nailfold capillaroscopy,
uncontrolled  Immunosuppressive and any association with
diabetes mellitus. therapeutic regimens have coexisting conditions or
The patients are been proposed, consisting of abnormal laboratory
phenotypically prednisone, parameters, which may
male, more than 40 cyclophosphamide, and aid in refining the
years of age. methotrexate, but evidence diagnosis
supporting their use is
anecdotal

12
Pia Angeli T. Reyes BSMT 1-1 HAPP: Tissue Pathology Journal Research

Source: Mesenchymal stem cell therapy in the treatment of hip osteoarthritis | Journal of Hip
Preservation Surgery | Oxford Academic (oup.com)

P I C O
P o p u l a ti o n P a ti e n t I n t e r v e n ti o n Comparison Outcome
Problem or Exposure

 A total of 10  all patients underwent the distinctiveness of this  Several techniques,

patients with bone marrow aspiration clinical study, as compared including micro
osteoarthritis in (30 ml) from the posterior to others, may well reside fracture, autologous
one or both hips iliac crest. In the case of in the two following chondrocyte
were enrolled in patients receiving BM- attributes, (i) the ex implantation, and
the study. Main MSC infusion on both legs, vivo MSC expansion mosaicplasty have
inclusion criteria the volume of bone procedure employed in this been used for the
included age ≥ 60 marrow aspiration was 60  study, privileged quality treatment of
years, radiological ml. Bone marrow aspirates than quantity of cell symptomatic
evidence of osteo- were sent to the GMP product to be administered chondral lesions in
degenerative facility for isolation and ex to the patient, and (ii) the hip.
disease changes vivo expansion of bone based in previous Nevertheless, to
(level to moderate) marrow-resident MSC. observations, the cell date there is still no
in one or both joint   the damaged hip (s) of product was administered definitive solution to
hip (s) and pain each patient received the to the patient, instead of 1 reproducibly
levels (refractory infusion of 20 × 106ex in 3 consecutive weekly replicate the load-
to analgesics vivo expanded BM-MSC. doses bearing capacity and
and/or hyaluronic After 7 and 14 consecutive durability of native
acid or cortisone days, patients received the joint cartilage
injection infusion of a second and a  Even though strong
treatment) ≥ 40 third dose of the respective evidence indicate
(Visual Analog cell product that clinical use of
Scale of 100 mm MSC is feasible and
safe, confirmation for
their clinical efficacy
still remain
controversial

13